Keflin, Kefzol, Mandol will be marketed in Abbott's I.V. admixture system, the firms announced Sept. 13. Release says the three drugs will be marketed in the system in "early 1985." Other Lilly drugs will be packaged in the system later. Letter of intent on the agreement was signed in June
You may also be interested in...
Can a false-claims suit be filed if doctors have different opinions about whether a treatment was necessary? The Supreme Court won’t say.
Despite turbulence in 2020 from the coronavirus pandemic as well as from difficulties relating to two of its key US generic launches, Hikma has reported solid full-year growth in both sales and profits across its business.
The firms' messenger RNA alliance inked back on 2013 is still very much ongoing but AstraZeneca decided to sell its considerable stake in the high-profile biotech to help finance its own pipeline.